Shows effects of glucose-lowering therapies on exacerbations in COPD, indicating varied outcomes.
Key Points Glucose‐lowering therapies differentially influence COPD outcomes beyond glycaemic control. SGLT‐2Is and GLP‐1RAs consistently reduce COPD exacerbations. Metformin shows modest benefit, while DPP‐4Is are largely neutral, and other agents show heterogeneous effects. Insulin is associated with a high risk of COPD exacerbations.
No takes yet. Share an insight, caveat, or question.
Cazzola et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: